AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39625244
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg daily starting post-operative day 2 until 1 day after chest tube removal
Trial: 39625478
Drug: Duvelisib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib (25 mg orally twice daily) with docetaxel (75 mg/m2 IV every 21-days)
Trial: 39625569
Drug: Standard neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neoadjuvant therapy with paclitaxel and adriamycin/cyclophosphamide
Trial: 39625696
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous 15 mg/kg amikacin dose
Trial: 39625696
Drug: Flat 1500-mg
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat 1500-mg dose
Trial: 39625696
Drug: Flat 3500-mg
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat 3500-mg dose
Trial: 39625696
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg dosing
Trial: 39625722
Drug: Fostamatinib, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib, 150 mg orally twice daily for 14 days
Trial: 39626074
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patches
Trial: 39626074
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for sertraline
Trial: 39626127
Drug: IV ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV ocrelizumab 600 mg every 24 weeks
Trial: 39626160
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg orally once daily on a 28-day cycle
Trial: 39626300
Drug: Inaticabtagene Autoleucel
RxNorm normalized name: Inaticabtagene Autoleucel
DrugBank: Inaticabtagene Autoleucel (DB18356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inaticabtagene Autoleucel (Inati-cel) infusion
Trial: 39626332
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT with CF)
Trial: 39626345
Drug: Adipocyte size
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipocyte size measurement in various fat depots (subcutaneous, visceral, retroperitoneal, mammary)
Trial: 39626378
Drug: Aβ-hTreg (VT301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aβ-hTreg (VT301) low dose
Trial: 39626378
Drug: Aβ-hTreg (VT301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aβ-hTreg (VT301) high dose
Trial: 39627123
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) interventions selected by an algorithm
Trial: 39627133
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitor (ICI) rechallenge
Trial: 39627217
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg daily for 12 months
Trial: 39627624
Drug: Submucosal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Submucosal dexamethasone (8 mg, 2 mL)
Trial: 39627701
Drug: RSM01 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSM01 (300 mg IV, 300 mg IM, 1000 mg IV, 3000 mg IV, 600 mg IM)
Trial: 39627786
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment for 2 weeks
Trial: 39627789
Drug: Adapted STAIR-NT
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted STAIR-NT intervention (massed treatment model with four 60-min sessions of skill building and two weeks of four 60-min sessions of narrative therapy)
Trial: 39627831
Drug: Active pulse
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pulse electromagnetic field therapy and standard exercise training
Trial: 39627831
Drug: Sham pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pulse electromagnetic field therapy and standard exercise training
Trial: 39628466
Drug: Polyphenol-rich supplement
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich supplement (specific dosage and duration not mentioned)
Trial: 39628618
Drug: Miglustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat (100 mg twice daily to 200 mg three times daily)
Trial: 39629185
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) and positive psychology therapy (PPT)
Trial: 39629675
Drug: Modified cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified cycles approach administered by an SLT and a student clinician
Trial: 39629836
Drug: CAM2038 subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM2038 subcutaneous (SC) buprenorphine (BPN) extended-release injections
Trial: 39629836
Drug: Daily sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sublingual (SL) BPN/naloxone (BPN/NX) tablets
Trial: 39630028
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid (OCA) treatment
Trial: 39630028
Drug: Non-OCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-OCA treatment (control)
Trial: 39630057
Drug: Modakafusp alfa
RxNorm normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modakafusp alfa at 1.5 mg/kg every 4 weeks (Q4W)
Trial: 39630057
Drug: Modakafusp alfa
RxNorm normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modakafusp alfa therapy
Trial: 39630067
Drug: Beta-lactam antibiotics
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam antibiotics (11 different types)
Trial: 39631702
Drug: D-Cycloserine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (100 mg) with daily intermittent theta-burst stimulation (iTBS)
Trial: 39631702
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with daily intermittent theta-burst stimulation (iTBS)
Trial: 39632107
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with cadonilimab (SOX regimen with cadonilimab)
Trial: 39633105
Drug: Automated text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated text messaging program prompting weekly BP checks for 6 months.
Trial: 39633112
Drug: Melatonin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 60 mg/day starting 5 days before surgery
Trial: 39633112
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment starting 5 days before surgery
Trial: 39633218
Drug: Plasma 10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma 10-15 ml/kg
Trial: 39633261
Drug: Educational booklet
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational booklet on falls prevention and behavioral treatment for urinary incontinence (control group)
Trial: 39633319
Drug: Therapist competence
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist competence (assessed using the Cognitive Therapy Scale-Revised)
Trial: 39633321
Drug: High-fiber dietary
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber dietary intervention (HFDI) with a target fiber of 50 g/day from whole foods
Trial: 39633321
Drug: Healthy control
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy control diet with a target fiber of 20 g/day
Trial: 39633367
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral health education materials (Control group).
Trial: 39633405
Drug: manual-based videoconferencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manual-based videoconferencing cognitive behavioral therapy (vCBT)
Trial: 39633570
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 2g administered within 45 minutes of symptom onset
Trial: 39633573
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose Heparin
Trial: 39635465
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg once daily for 12 weeks
Trial: 39636384
Drug: Super-resolution ultrasound
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super-resolution ultrasound (SR-US) imaging after bolus injection of microbubbles at clinical concentration
Trial: 39636496
Drug: Initiating medications
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initiating medications for opioid use disorder (MOUD) prior to release
Trial: 39636496
Drug: Linkage to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linkage to ongoing MOUD treatment in the community
Trial: 39636496
Drug: Peer support-facilitated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support-facilitated treatment retention efforts
Trial: 39636502
Drug: Remote, tablet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote, tablet-based patient video education intervention focused on cancer care coordination
Trial: 39636623
Drug: Intratumoral delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral delivery of conventional type 1 dendritic cells (cDC1), 6 times weekly, followed by paclitaxel (80 mg/m2, intravenously, 12 times weekly), trastuzumab (8 mg/kg loading dose, then 6 mg/kg), and pertuzumab (840 mg loading dose, then 420 mg) every 3 weeks for 6 cycles starting from day 1 of cDC1 injections.
Trial: 39636638
Drug: Psilocybin, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin, 25 mg
Trial: 39636638
Drug: Niacin, 100
RxNorm normalized name: Niacin, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin, 100 mg
Trial: 39636679
Drug: Oral screen
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral screen training for 12 weeks
Trial: 39636679
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral screen training)
Trial: 39637307
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus hypomethylating agents
Trial: 39637726
Drug: Brivaracetam (≤5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (≤5 mg/kg/day, ≤200 mg/day)
Trial: 39637944
Drug: Tremelimumab +
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab + Durvalumab (T300/D) as neoadjuvant treatment
Trial: 39637944
Drug: Tremelimumab +
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab + Durvalumab (T300/D) as definitive treatment
Trial: 39638148
Drug: Oral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-citrulline supplementation
Trial: 39638275
Drug: Catheter-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-directed therapy (CDT) plus anticoagulation
Trial: 39638585
Drug: ACTION (Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTION (Acceptance and Commitment Therapy Intervention when Opioids are Necessary)
Trial: 39638596
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment followed by application of autologous bioartificial palate mucosa
Trial: 39638596
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment (control group)
Trial: 39638782
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pembrolizumab with bevacizumab and oral cyclophosphamide
Trial: 39639282
Drug: Creative writing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative writing intervention combined with standard treatment
Trial: 39640075
Drug: Uchasingihwan (UCSGH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uchasingihwan (UCSGH) 2.5 g granule three times a day for six weeks
Trial: 39640075
Drug: loxoprofen 60
RxNorm normalized name: loxoprofen 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loxoprofen 60 mg tablet three times a day for six weeks
Trial: 39641169
Drug: Daily avocado
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily avocado consumption
Trial: 39641725
Drug: FFR-guided PCI
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-guided PCI with current generation drug-eluting stents (DES)
Trial: 39641856
Drug: Anidulafungin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (200 mg on day 1, then 100 mg daily)
Trial: 39641926
Drug: DPYD/UGT1A1 pharmacogenetic-informed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD/UGT1A1 pharmacogenetic-informed therapy
Trial: 39641985
Drug: Self-help program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help program intervention delivered via an automated conversational agent on WhatsApp
Trial: 39642315
Drug: Fitusiran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran (50 mg or 80 mg)
Trial: 39642315
Drug: Fitusiran (AT-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran (AT-based dose regimen)
Trial: 39642783
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure Therapy with financial incentives (PE+)
Trial: 39644535
Drug: HAI-FUDR (Hepatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI-FUDR (Hepatic Arterial Infusion of Floxuridine)
Trial: 39644535
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic chemotherapy only (non-HAI group)
Trial: 39644858
Drug: Aromatic solution
RxNorm normalized name: ALKALINE AROMATIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic solution (lavender and ginger oil) applied as a mouth spray at 0, 2, 4, 6, and 8 hours postoperatively
Trial: 39644858
Drug: Placebo mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouth spray
Trial: 39644907
Drug: Mitapivat 50
RxNorm normalized name: mitapivat 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitapivat 50 mg
Trial: 39644907
Drug: Mitapivat 100
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitapivat 100 mg
Trial: 39645270
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of β-blocker therapy
Trial: 39647494
Drug: MenABCWY (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY (two doses at months 0 and 6)
Trial: 39647494
Drug: 4CMenB (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB (two doses at months 0 and 6)
Trial: 39647494
Drug: MenACWY-CRM (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (one dose at month 0)
Trial: 39647798
Drug: Placebo (standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard-of-care antibiotics)
Trial: 39648079
Drug: Chef-ID intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chef-ID intervention (12-week program including weekly group sessions for cooking skills, nutrition education, and exercise)
Trial: 39648217
Drug: Anlotinib plus
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib plus chemotherapy
Trial: 39648614
Drug: Islatravir 60
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 60 mg single oral dose
Trial: 39648614
Drug: Standard methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methadone therapy
Trial: 39648796
Drug: Daily chicken
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chicken egg intake for 6 months
Trial: 39649135
Drug: CD40.HIVRI.Env (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD40.HIVRI.Env (0.3, 1.0, or 3.0 mg) alone or co-administered with DNA-HIV-PT123
Trial: 39651334
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) therapy
Trial: 39651791
Drug: Blinatumomab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab plus chemotherapy (average relapse risk)
Trial: 39651791
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (average relapse risk)
Trial: 39651791
Drug: Blinatumomab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab plus chemotherapy (high relapse risk)
Trial: 39651791
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (high relapse risk)
Trial: 39651882
Drug: BRII-693 (10-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRII-693 (10-400 mg single dose)
Trial: 39651882
Drug: BRII-693 (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRII-693 (100-200 mg 7-day repeat dose)
Trial: 39651882
Drug: BRII-693 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRII-693 (150 mg 14-day repeat dose)
Trial: 39651931
Drug: 23ME-00610 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23ME-00610 (2 mg initially, then 1400 mg Q3W)
Trial: 39651931
Drug: 23ME-00610 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23ME-00610 (doses ≥ 60 mg)
Trial: 39652211
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at acupoints LI4, SJ6, ST36, and ST37, administered twice daily from the day of surgery until the fourth day after the operation
Trial: 39652211
Drug: Sham-electroacupuncture (SA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-electroacupuncture (SA), administered twice daily from the day of surgery until the fourth day after the operation
Trial: 39652826
Drug: Intravenous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous daratumumab 16 mg/kg (Long intense)
Trial: 39652826
Drug: Intravenous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous daratumumab 16 mg/kg (Intermediate)
Trial: 39652826
Drug: Intravenous daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous daratumumab 16 mg/kg (Short intense)
Trial: 39652866
Drug: Usual physiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual physiotherapy (control group) consisting of protocolized breathing exercises (8 times daily for 10 minutes) and physical exercises (2 times daily for 10 minutes)
Trial: 39653044
Drug: Tezepelumab 420
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 420 mg subcutaneously every 4 weeks for up to 52 weeks
Trial: 39653116
Drug: HBI0101 anti-BCMA
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBI0101 anti-BCMA CART therapy, infused with 800 × 10 after lymphodepletion
Trial: 39653116
Drug: HBI0101 anti-BCMA
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBI0101 anti-BCMA CART therapy
Trial: 39653325
Drug: Mavacamten treatment
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mavacamten treatment
Trial: 39653554
Drug: Neoadjuvant PD-1
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant PD-1 inhibitors in combination with chemotherapy
Trial: 39653573
Drug: Tailor-made nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailor-made nutrition therapy consisting of oral nutritional supplements and supplementary parenteral nutrition for 10 days
Trial: 39653676
Drug: Oral tenofovir-based
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tenofovir-based PrEP with point-of-care urine tenofovir testing and adherence counselling
Trial: 39654273
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (alteplase 0.90 mg/kg or conservative management)